Picture of 4D Molecular Therapeutics logo

FDMT 4D Molecular Therapeutics Cashflow Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMid CapHigh Flyer

Annual cashflow statement for 4D Molecular Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

2019
December 31st
2020
December 31st
2021
December 31st
2022
December 31st
2023
December 31st
Period Length:12 M12 M12 M12 M12 M
Source:PROSPECTUS10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Net Income/Starting Line-49.3-56.7-71.3-107-101
Depreciation
Non-Cash Items11.35.0516.219.720.2
Unusual Items
Purchased R&D
Other Non-Cash Items
Changes in Working Capital0.259-0.711-15.5-1.340.63
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Other Liabilities
Cash from Operating Activities-36.7-50.9-69.1-86.7-75.8
Capital Expenditures-3.2-1-9.11-11.5-2.77
Purchase of Fixed Assets
Other Investing Cash Flow Items-164-5.51118
Sale/Maturity of Investment
Purchase of Investments
Cash from Investing Activities-3.2-1-173-17.1116
Financing Cash Flow Items-2.27-0.4680
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Cash from Financing Activities-2.192791183.08157
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash-42.1227-124-101197